- Conditions
- Hypertension, Self-Management, Technology, Quality of Life
- Interventions
- OPTIMA-BP Intervention
- Behavioral
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–18
of 18
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hypertension
- Interventions
- Azilsartan medoxomil with or without add-on chlorthalidone, Azilsartan medoxomil with or without add-on hydrochlorothiazide
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 669 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 39
- States / cities
- Ozark, Alabama • Tallassee, Alabama • Long Beach, California + 36 more
- Conditions
- Essential Hypertension, Older Adults
- Interventions
- chlorthalidone, Placebo
- Drug · Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Type 1 Diabetes Mellitus, Hypercalciuria
- Interventions
- Chlorthalidone
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Hypertension
- Interventions
- Chlorthalidone 12.5 mg, Hydrochlorothiazide 25 mg, Placebo
- Drug
- Lead sponsor
- Creighton University
- Other
- Eligibility
- 19 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Hypertension
- Interventions
- Study#1: chlorthalidone (CTD), titrated dose, Study #1: spironolactone (SP), titrated dose, Study# 2 chlorthalidone (CTD), fixed dose, Study# 2 spironolactone (SP), fixed dose, Study# 2 irbsesartan (IR), fixed dose
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Hypertension
- Interventions
- Anti-hypertensive agent: amlodipine, Anti-hypertensive agent: Chlorthalidone, Anti-hypertensive agent: Losartan, Home BP monitoring with cuffed device, Home BP monitoring with cuffed device + BP patch, Home BP monitoring with cuffed device + BP watch
- Drug · Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Hypertension
- Interventions
- Amlodipine, Chlorthalidone, Losartan
- Drug
- Lead sponsor
- Anthony J Viera, MD, MPH
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Essential Hypertension
- Interventions
- Azilsartan medoxomil and chlorthalidone, Azilsartan medoxomil and hydrochlorothiazide
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Gulf Shores, Alabama • Scottsboro, Alabama + 47 more
- Conditions
- Renal Insufficiency, Chronic, Hypertension
- Interventions
- Chlorthalidone, Placebo
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Hypertension
- Interventions
- Chlorthalidone 12.5 mg, Hydrochlorothiazide 25 mg, Aspirin 81 mg
- Drug
- Lead sponsor
- Creighton University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Hypertension, Vascular Stiffness, Aging
- Interventions
- Blood pressure treatment algorithm
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 60 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin
- Conditions
- Hypertension, Left Ventricular Hypertrophy
- Interventions
- Eplerenone, Chlorthalidone, Potassium
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypertension
- Interventions
- Azilsartan medoxomil and chlorthalidone, Chlorthalidone, Azilsartan medoxomil
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 84
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Tuscaloosa, Alabama + 81 more
- Conditions
- Essential Hypertension
- Interventions
- Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil-hydrochlorothiazide
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,085 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Haleyville, Alabama • Hueytown, Alabama + 67 more
- Conditions
- Essential Hypertension
- Interventions
- Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil and hydrochlorothiazide
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,071 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 84
- States / cities
- Gulf Shores, Alabama • Litchfield Park, Arizona • Mesa, Arizona + 81 more
- Conditions
- Hypertension
- Interventions
- Hydrochlorothiazide (HCTZ), Chlorthalidone (CTD)
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 65 Years and older
- Enrollment
- 20,723 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fayetteville, Arkansas + 64 more
- Conditions
- Resistant Hypertension in Kidney Transplant Patients
- Interventions
- Chlorthalidone
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Richmond, Virginia